What is the KPV peptide, and what does the research show?
KPV peptide is Lys-Pro-Val, the three-amino-acid C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Published preclinical work shows anti-inflammatory activity, primarily in rodent colitis models and in skin and wound research, by quieting NF-κB signaling within cells rather than acting on a surface receptor. As a clinician who has read this literature closely while running peptide protocols, my honest read is that the signal is consistent, but the evidence is at the research stage. There are no human efficacy trials. Here is what the studies actually report.
What is the KPV peptide?
KPV is a tripeptide made of lysine (K), proline (P), and valine (V). It corresponds to residues 11 to 13 of alpha-MSH, the C-terminal tail of that larger hormone [1]. Alpha-MSH itself is cleaved from pro-opiomelanocortin and signals through the melanocortin receptors that drive pigmentation and immune modulation. KPV is the interesting part because it keeps the anti-inflammatory behavior while shedding the receptor-binding sequence.
That last point is the one most worth sitting with. In a 2010 review, Brzoska and colleagues note that KPV “lacks the entire sequence motif required for binding to any of the known” melanocortin receptors, yet “retains almost all of the anti-inflammatory capacity of the full hormone” [2]. So whatever KPV does, it is not doing it the way alpha-MSH does. Researchers study it as a research-use compound, and Healius supplies it on that basis KPV. Every batch is identity-confirmed by mass spectrometry and purity-tested through our in-house and third-party lab-testing program, which matters more for a short peptide than people expect, because synthesis truncates. Counterion artifacts can confound an anti-inflammatory assay.
How does KPV reduce inflammation in research models?
In the published models, KPV enters cells via PepT1, a di- and tripeptide transporter, and then interferes with the NF-κB and MAPK pathways that activate inflammatory genes. The landmark 2008 *Gastroenterology* study by Dalmasso and colleagues showed human PepT1 transports KPV with a Km of about 160 micromolar in intestinal epithelial cells, and that KPV was active at nanomolar concentrations, around 10 nanomolar in vitro [3]. Inside the cell, it reduced NF-κB activation and pro-inflammatory cytokine secretion.
Two features make this mechanism distinctive. First, it is receptor-independent. In a peritonitis model, Getting and colleagues found that a melanocortin MC3/4 antagonist did not block KPV’s effect or raise cAMP, suggesting interference with interleukin-1-beta signaling rather than classic receptor activation [4]. Second, PepT1 is upregulated in inflamed colon tissue but not in healthy colon tissue, so in these models, the transporter concentrates KPV where inflammation already exists [3]. That is an elegant piece of biology, and it is why the colitis literature is the most developed part of the KPV evidence base. It also explains why a peptide this small can act orally in animal studies: PepT1 is built to ferry di- and tri-peptides across the gut wall, so the same transporter that handles dietary protein fragments handles KPV.
What has KPV been studied for in the gut and skin?
Gut inflammation is the headline. In the Dalmasso work, oral KPV at 100 micromolar in drinking water reduced myeloperoxidase activity, a neutrophil marker, by roughly 50 percent in dextran-sodium-sulfate colitis and roughly 30 percent in TNBS colitis, with significant drops in IL-6 and IL-12 [3]. An independent 2008 group reported earlier recovery, stronger body-weight regain, and reduced inflammatory infiltrate in two colitis models [5]. More recent work has focused on getting KPV to the colon intact: a 2017 study used hyaluronic-acid nanoparticles dosed at 16 micrograms per kilogram and saw histology close to healthy controls plus dose-dependent epithelial wound recovery [6], and a 2024 nanoparticle design pairing KPV with tacrolimus reached 100 percent survival versus 70 percent in chronic colitis controls [7].
The skin and wound data are smaller but real. KPV reduces TNF-alpha-driven NF-kB activation in keratinocytes, and an older study found that alpha-MSH and KPV reduced the viability of Staphylococcus aureus and Candida albicans even at picomolar levels [8]. This healing and anti-inflammatory direction is why KPV sits alongside compounds covered in our overview of injury and tissue repair peptides.
KPV vs BPC-157: how do they differ?
KPV and BPC-157 are grouped because both appear in gut and healing research, but they are different molecules with different roles. KPV is a 3-amino-acid fragment of alpha-MSH whose main documented action is dampening NF-kB-driven inflammation. BPC-157 is a 15-amino-acid sequence studied mainly for angiogenesis and cytoprotection, a repair-and-regrow profile rather than an inflammation-quieting one BPC-157. In my own published clinical observation work on combination tissue-healing protocols, I have framed peptides as tools matched to a mechanism, not as interchangeable [9]; KPV and BPC-157 are a clear example of that principle.
On dosing, the honest answer is that the figures above are research parameters from animal and cell studies, not human recommendations. Healius does not provide human dosing because none of this work has progressed to human efficacy trials. The U.S. FDA’s compounding advisory committee was scheduled to review KPV in mid-2026, which tells you the regulatory status is still being worked out. Treat any number you see as a research data point, and read the primary literature in the References below rather than a dosing chart.
References
- Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews. 2008;29(5):581-602. DOI: 10.1210/er.2007-0027. PMID: 18612139.
- Brzoska T, Böhm M, Lügering A, Loser K, Luger TA. Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone-related peptides beyond the pharmacophore. Advances in Experimental Medicine and Biology. 2010;681:107-116. DOI: 10.1007/978-1-4419-6354-3_8. PMID: 21222263.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. DOI: 10.1053/j.gastro.2007.10.026. PMID: 18061177.
- Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics. 2003;306(2):631-637. DOI: 10.1124/jpet.103.051623. PMID: 12750433.
- Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331. DOI: 10.1002/ibd.20334. PMID: 18092346.
- Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy. 2017;25(7):1628-1640. DOI: 10.1016/j.ymthe.2016.11.020. PMID: 28143741.
- Zhang D, Jiang L, Yu F, Yan P, Liu Y, Wu Y, et al. PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced colitis. Frontiers in Pharmacology. 2024;15:1442876. DOI: 10.3389/fphar.2024.1442876.
- Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology. 2000;67(2):233-239. DOI: 10.1002/jlb.67.2.233. PMID: 10670585.
- Patterson M, Reeves K, Singh A. Combination peptide protocols for tissue healing: clinical decision-making in regenerative medicine. International Journal of Functional and Integrative Medicine. 2023;6(2):78-91.
Research Use Only Disclaimer
Healius Peptides products are sold for in vitro research use only and are not intended for human or veterinary use, diagnosis, treatment, or prevention of any condition.
Frequently Asked Questions About KPV and Anti-Inflammatory Peptides
In published preclinical research, KPV reduces inflammatory signaling inside cells. It enters via the PepT1 transporter and reduces activation of the NF-κB and MAPK pathways, thereby reducing the production of cytokines such as IL-6 and TNF-α [3]. These are laboratory and animal findings, not human effects demonstrated, and KPV is supplied for research use only.
The most developed research use is as a model anti-inflammatory compound in studies of colitis and inflammatory bowel disease, with a smaller literature in skin, wound, and antimicrobial models [5][8]. Its appeal to researchers lies in its receptor-independent mechanism and the oral stability of this small peptide. None of this establishes a human therapeutic use.
They are different compounds with different mechanisms. KPV is a 3-residue alpha-MSH fragment studied for NF-kB-driven anti-inflammatory activity; BPC-157 is a 15-residue peptide studied for angiogenesis and tissue protection. Researchers select between them based on the mechanism a protocol probes, and both remain research-use-only compounds.
Published studies report figures such as 10 nanomolar in vitro, 100 micromolar after oral dosing in rodent colitis models, and 16 micrograms per kilogram in a nanoparticle delivery study [3][6]. These are experimental parameters for in vitro and animal work. Healius does not provide human dosing guidance, and no human dosing has been established.
No. KPV is not approved as a medicine in any major market, and there are no completed human efficacy trials. It is studied as a research compound, and its regulatory status was still under active review, including by the U.S. FDA’s compounding advisory committee in 2026. It is sold strictly for in vitro research use.
In research models, yes. Because it is a tripeptide that PepT1 can transport, KPV survives gastrointestinal transit better than most larger peptides, and several studies have used oral or orally targeted nanoparticle delivery in animals [3][6]. This is a research observation about the compound’s chemistry, not a usage instruction.
Leave a Reply